{
    "clinical_study": {
        "@rank": "156277", 
        "arm_group": [
            {
                "arm_group_label": "R348 Ophthalmic Solution, 0.2%", 
                "arm_group_type": "Active Comparator", 
                "description": "R348 Ophthalmic Solution, 0.2%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day."
            }, 
            {
                "arm_group_label": "R348 Ophthalmic Solution, 0.5%", 
                "arm_group_type": "Active Comparator", 
                "description": "R348 Ophthalmic Solution, 0.5%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day."
            }, 
            {
                "arm_group_label": "R348 Ophthalmic Solution, 1.0%", 
                "arm_group_type": "Active Comparator", 
                "description": "R348 Ophthalmic Solution, 1.0%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, single (1 day) or multiple ascending dose (13 days) followed by a single dose on the fourteenth day."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety, tolerability and pharmacokinetics of\n      R348 eye drops in patients with dry eye disease."
        }, 
        "brief_title": "A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Keratoconjunctivitis Sicca", 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, double-blind, placebo-controlled single and multiple ascending dose\n      study to evaluate the ocular tolerability, safety, and pharmacokinetics of R348 administered\n      in patients with mild to moderate keratoconjunctivitis sicca (KCS)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Mild to moderate Keratoconjunctivitis Sicca.\n\n          -  A corrected visual acuity in both eyes of 20/40 or better.\n\n          -  An intraocular pressure of < 21 mm Hg with a difference between eyes of < 6 mm Hg.\n\n        Exclusion Criteria:\n\n          -  History or evidence of ocular infection, inflammation, or conjunctivitis within 2\n             months prior to the first dosing day.\n\n          -  History or evidence of blepharitis requiring the use of antibiotics or eye scrubs\n             within 2 months prior to the first dosing day.\n\n          -  History of herpes simplex keratitis at any time.\n\n          -  Current ocular allergy symptoms.\n\n          -  Recent use of eye medications such as steroids or cyclosporine\n\n          -  Refractive eye surgery within 12 months of the first dosing day.\n\n          -  Other eye surgeries within 4 months of the first dosing day.\n\n          -  Current use of contact lenses or discontinuation of contact lens use within 2 weeks\n             of the first dosing day.\n\n          -  Receipt of any blood or blood products within 90 days prior to the first dosing day.\n\n          -  Participation in any clinical study within 30 days prior to the first dosing day.\n\n          -  History of disease, or currently have a significant illness or abnormal laboratory\n             finding as determined by your study doctor.\n\n          -  Positive for hepatitis B, hepatitis C or HIV.\n\n          -  Smoked regularly within 12 months of first dosing day.\n\n          -  History of substance abuse, drug addiction or alcoholism."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733992", 
            "org_study_id": "C-932348-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "R348 Ophthalmic Solution, 0.2%", 
                "description": "R348 Ophthalmic Solution, 0.2% single and multiple ascending dose", 
                "intervention_name": "R348 Ophthalmic Solution, 0.2%", 
                "intervention_type": "Drug", 
                "other_name": "R932348"
            }, 
            {
                "arm_group_label": "R348 Ophthalmic Solution, 0.5%", 
                "description": "R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose", 
                "intervention_name": "R348 Ophthalmic Solution, 0.5%", 
                "intervention_type": "Drug", 
                "other_name": "R932348"
            }, 
            {
                "arm_group_label": "R348 Ophthalmic Solution, 1.0%", 
                "description": "R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose", 
                "intervention_name": "R348 Ophthalmic Solution, 1.0%", 
                "intervention_type": "Drug", 
                "other_name": "R932348"
            }, 
            {
                "arm_group_label": [
                    "R348 Ophthalmic Solution, 0.2%", 
                    "R348 Ophthalmic Solution, 0.5%", 
                    "R348 Ophthalmic Solution, 1.0%", 
                    "Placebo"
                ], 
                "description": "Placebo, single and multiple ascending dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Andover", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01810"
                }, 
                "name": "Andover Eye Associates"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Pharmacokinetics, Tolerability and Safety Study of R932348 Ophthalmic Solution in Patients With Mild to Moderate Keratoconjunctivitis Sicca", 
        "other_outcome": {
            "measure": "Change in Schirmer test", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and Visits 4, 8 and 12"
        }, 
        "overall_official": {
            "affiliation": "Andover Eye Associates", 
            "last_name": "Gail Torkildsen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in corneal fluorescein staining", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and Visits 4, 8 and 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733992"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in conjunctival lissamine green staining", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and Visits 4, 8 and 12"
        }, 
        "source": "Rigel Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rigel Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}